Hair Loss on Semaglutide: Facts vs Myths

Hair loss (alopecia) was reported in approximately 3% of patients taking Wegovy® (semaglutide 2.4 mg) in the STEP clinical trials, compared to about 1% on placebo. The shedding is almost always telogen effluvium — a temporary, diffuse form of hair loss triggered by rapid weight change and caloric restriction — not permanent baldness. Most people see regrowth within 3 to 6 months once weight and nutrition stabilize.

Does semaglutide directly cause hair loss?

This is one of the most common myths. Current evidence suggests that semaglutide does not directly damage hair follicles. Instead, the hair shedding is linked to the rapid and significant weight loss the medication produces. Any method of losing a large amount of weight quickly — whether surgery, very-low-calorie diets, or GLP-1 medications — can trigger the same type of temporary hair loss.

A 2025 retrospective study published on medRxiv found that patients taking semaglutide had a 52% higher risk of hair loss compared to those taking Contrave (naltrexone–bupropion), a weight-loss medication associated with slower, more gradual weight reduction. Women on semaglutide had more than twice the risk compared to women in the Contrave group, further supporting the idea that the speed and magnitude of weight loss — rather than the drug itself — is the primary trigger.

What is telogen effluvium and why does it happen during weight loss?

Telogen effluvium is a condition where a larger-than-normal number of hair follicles shift from the active growth phase (anagen) into the resting phase (telogen) at the same time. Normally, about 5–10% of your hair is in the telogen phase at any given time. When the body experiences a significant stress — such as rapid weight loss, major surgery, or severe illness — that percentage can jump to 30% or more, leading to noticeable shedding.

The shedding typically begins 2 to 3 months after the triggering event, which is why many people on semaglutide first notice hair loss a few months into treatment, often around or after a dose increase. According to the Cleveland Clinic, telogen effluvium is self-limiting, and approximately 95% of patients experience full regrowth within 3 to 6 months once the stressor resolves.

How common is hair loss on GLP-1 medications?

The clinical trial data shows that hair loss is a recognized but relatively uncommon side effect across GLP-1 medications. Importantly, the risk appears to increase with the amount of weight lost, not simply with the medication dose.

In Wegovy trials, participants who lost more than 20% of their body weight reported alopecia at a rate of 5.3%, compared to 2.5% in those who lost less than 20%. This dose-independent, weight-loss-dependent pattern reinforces that the shedding is driven by the metabolic stress of rapid weight change rather than a direct pharmacological effect.

Who is most at risk for hair shedding on semaglutide?

Based on available data, several factors may increase the likelihood of experiencing hair loss while taking semaglutide or other GLP-1 medications:

• Greater weight loss. Patients who lose more than 15–20% of their body weight appear to be at higher risk than those with more modest losses.
• Women. Data from the SURMOUNT-1 trial showed that 7.1% of women experienced hair shedding compared to less than 1% of men. Hormonal factors may play a role in this disparity.
• Rapid dose escalation. Faster titration schedules may lead to quicker weight loss and more pronounced metabolic stress.
• Low caloric and protein intake. Reduced appetite — one of the intended effects of GLP-1 medications — can lead to insufficient intake of nutrients critical for hair health, especially if food choices are limited.
• Pre-existing nutritional deficiencies. People who are already low in iron, zinc, vitamin D, or biotin before starting treatment may be more vulnerable.

What nutrients matter most for hair health on GLP-1 medications?

Hair is primarily made of keratin, a protein, so adequate protein intake is essential. Research suggests aiming for approximately 1.0 to 1.2 grams of protein per kilogram of body weight daily while on GLP-1 therapy. Beyond protein, several micronutrients play important roles in the hair growth cycle:

• Iron. Iron carries oxygen to hair follicles and supports their growth phase. Low ferritin levels are a well-established trigger for telogen effluvium.
• Zinc. Zinc supports hair follicle structure and the function of oil glands around follicles. Deficiency is associated with diffuse hair shedding.
• Biotin (vitamin B7). Biotin supports keratin production. However, high-dose biotin supplements can interfere with laboratory test results — including thyroid function and cardiac troponin assays — so it is important to discuss supplementation with a healthcare provider.
• Vitamin D. Low vitamin D levels have been linked to telogen effluvium in multiple studies. Many patients with obesity have suboptimal vitamin D status before starting GLP-1 treatment.

Because appetite is often significantly reduced on GLP-1 medications, it can be difficult to meet these nutritional targets through food alone. Tracking what you eat — even roughly — can help identify gaps. Glone's food-tracking features can make it easier to keep an eye on protein and overall intake alongside your medication routine.

Can you prevent hair loss while taking semaglutide?

There is no guaranteed way to prevent telogen effluvium during rapid weight loss, but several evidence-based strategies may reduce the risk or severity:

• Prioritize protein at every meal. Aim for 1.0–1.2 g/kg/day of protein. Even when appetite is low, small protein-rich meals or snacks (Greek yogurt, eggs, lean meat, protein shakes) can help maintain intake.
• Follow the titration schedule. Sticking to the recommended dose titration schedule rather than escalating doses too quickly may help moderate the pace of weight loss.
• Check nutrient levels with your provider. A simple blood panel for ferritin, zinc, vitamin D, and B12 can identify deficiencies that are easily correctable with supplementation.
• Stay hydrated. Dehydration — which can result from nausea and vomiting on GLP-1 medications — adds physiological stress and may worsen shedding.
• Be gentle with your hair. Avoid tight hairstyles, excessive heat styling, and harsh chemical treatments during periods of active shedding. These can cause additional mechanical damage to weakened follicles.

When does hair grow back after shedding on semaglutide?

For most people, the shedding is temporary. Telogen effluvium typically resolves on its own once the triggering stress (rapid weight change) stabilizes. According to dermatological literature, noticeable regrowth usually begins within 3 to 6 months after weight loss slows and nutritional intake improves.

It is important to understand that the hair you see falling out has already been in the resting phase for weeks. By the time you notice the shedding, new hairs are often already beginning to grow underneath. The visible thinning may feel alarming, but in the vast majority of cases it is not a sign of permanent hair loss.

If hair loss persists beyond 6 months, becomes patchy rather than diffuse, or is accompanied by scalp itching or redness, it is important to see a dermatologist. These could be signs of a different type of alopecia that requires specific treatment.

What are the myths about semaglutide and hair loss?

Several misconceptions circulate online. Here are the most common ones, clarified by the clinical evidence:

• Myth: Semaglutide permanently damages hair follicles. Fact: Telogen effluvium does not involve follicle destruction. The follicles remain intact and are capable of producing new hair once the stressor resolves.
• Myth: Everyone on semaglutide will lose hair. Fact: Only about 3% of patients in clinical trials reported alopecia — the vast majority of patients do not experience noticeable hair shedding.
• Myth: Hair loss means you should stop your medication. Fact: The decision to adjust or discontinue medication should be made with a healthcare provider, weighing the benefits of treatment against side effects. Stopping the medication does not guarantee immediate regrowth, and the underlying weight loss is the primary trigger.
• Myth: Biotin supplements will definitely fix it. Fact: Biotin may help if you have a genuine deficiency, but high-dose biotin supplements can interfere with lab tests and may not address the root cause, which is often the pace of weight loss rather than a single nutrient gap.
• Myth: Hair loss only happens with semaglutide, not tirzepatide. Fact: The SURMOUNT-1 trial for Zepbound (tirzepatide) reported alopecia rates of up to 5.7% at the 15 mg dose — actually higher than the 3% seen with Wegovy. Both medication classes carry similar risk because the mechanism is related to weight loss.

When should you talk to a healthcare provider about hair loss?

Some degree of hair shedding may be expected during significant weight loss, but certain patterns warrant a conversation with your healthcare provider or a dermatologist:

• Hair loss that continues for more than 6 months without improvement.
• Patchy bald spots rather than overall thinning.
• Scalp tenderness, itching, redness, or scaling.
• Hair loss accompanied by other symptoms such as extreme fatigue, brittle nails, or feeling unusually cold — which may suggest a thyroid issue or significant nutritional deficiency.

A provider can run blood work to check for treatable causes like iron deficiency, thyroid dysfunction, or hormonal imbalances. In some cases, they may recommend adjusting the medication dose or slowing the titration to moderate the pace of weight loss. For a broader view of side effects over time, see our guide on Ozempic side effects week by week.

Sources

• FDA Prescribing Information for Wegovy (semaglutide) — accessdata.fda.gov
• FDA Prescribing Information for Zepbound (tirzepatide) — accessdata.fda.gov
• Alopecia and Semaglutide: Connecting the Dots for Patient Safety (2025) — pmc.ncbi.nlm.nih.gov
• Risk of Hair Loss with Semaglutide for Weight Loss (2025) — medrxiv.org
• SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity (2022) — pubmed.ncbi.nlm.nih.gov
• Telogen Effluvium — Cleveland Clinic — my.clevelandclinic.org
• Telogen Effluvium — StatPearls / NIH — ncbi.nlm.nih.gov